| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Income (loss) from continuing operations | 2,154 | -10,256 |
| Stock-based compensation | 21,376 | 13,610 |
| Depreciation and amortization | 2,088 | 1,047 |
| Amortization of deferred contract costs | 1,175 | 746 |
| Amortization of debt discount and issuance costs | 0 | 0 |
| Amortization of operating lease right-of-use assets | 350 | 199 |
| Accelerated amortization of right-of-use asset in connection with lease abandonment | 0 | - |
| Gain on investment in equity securities | 16,580 | 0 |
| Loss on extinguishment of debt | 0 | 0 |
| Gain on sale of insurance business | 0 | - |
| Other | 355 | 316 |
| Trade and other receivables | -2,345 | 364 |
| Prepaid expenses and other assets, current and non-current | 4,709 | 1,262 |
| Deferred contract costs, non-current | 268 | 531 |
| Accounts payable | -848 | -419 |
| Deferred revenue | 5,313 | 12,734 |
| Accrued compensation | 966 | -684 |
| Operating lease liabilities | -2,633 | -1,921 |
| Other liabilities, current and non-current | 1,686 | 2,210 |
| Net cash provided by (used in) operating activities - continuing operations | 12,060 | 14,793 |
| Net cash used in operating activities - discontinued operations | -1,528 | -771 |
| Net cash provided by (used in) operating activities | 10,532 | 14,022 |
| Purchases of marketable securities | 30,490 | 23,749 |
| Sale of available-for-sale securities | 20,827 | 859 |
| Maturities of marketable securities | 44,227 | 27,727 |
| Additions to property, equipment and internal-use software development costs | 10,592 | 8,320 |
| Other | 0 | - |
| Proceeds from sale of insurance business | 0 | - |
| Investment in non-marketable equity securities | 4,000 | 4,000 |
| Net cash provided by investing activities - continuing operations | 19,972 | -7,483 |
| Net cash used in investing activities - discontinued operations | -182 | -120 |
| Net cash provided by investing activities | 19,790 | -7,603 |
| Proceeds from exercises of stock options, including early exercises, net of repurchases | 1,505 | 793 |
| Taxes paid related to net share settlement of equity awards | 7,388 | 5,502 |
| Share repurchases | 9,143 | 4,118 |
| Repayment of long-term debt | 0 | 0 |
| Net proceeds from the issuance of the series a redeemable convertible preferred stock and the haveli warrant | 0 | 0 |
| Payment for issuance costs related to the series a redeemable convertible preferred stock and the haveli warrant | 0 | 0 |
| Net cash used in financing activities - continuing operations | -15,026 | -8,827 |
| Effect of exchange rates on cash, cash equivalents, and restricted cash | 0 | 0 |
| Net increase in cash, cash equivalents, and restricted cash | 15,296 | -2,408 |
| Cash and cash equivalents at beginning of period | 49,537 | - |
| Cash and cash equivalents at end of period | 64,833 | - |
Blend Labs, Inc. (BLND)
Blend Labs, Inc. (BLND)